Xyntha 250 Unit (Moroctocog Alfa KIT) 250 UNIT

Xyntha 250 Unit is a pharmaceutical product containing Moroctocog Alfa, used for managing bleeding episodes in hemophilia A. This intravenous kit includes a 250 IU dose with a 4 mL diluent, manufactured by Pfizer Canada ULC.

Strength

250 UNIT

Pack Size

250IU -4ML DILUENT

Manufacturer / TM Owner

PFIZER CANADA ULC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Xyntha 250 Unit is primarily used to control and prevent bleeding episodes in individuals with hemophilia A, a condition characterized by a deficiency in clotting factor VIII. Moroctocog Alfa, the active ingredient, helps to replace the missing clotting factor, aiding in blood coagulation. This medication is often administered intravenously to manage bleeding episodes effectively.

Side Effects

Common effects of Xyntha 250 Unit may include localized reactions at the injection site, such as redness or swelling. Some users might experience mild symptoms like headache or nausea. These effects are generally temporary and subside as the body adjusts to the medication.

Precautions & Warnings

Xyntha 250 Unit should be handled with care, ensuring proper storage and administration as directed by a healthcare professional. It is important to monitor for any signs of allergic reactions or unusual bleeding. Users should inform their healthcare provider about any pre-existing conditions or medications they are taking.

Avoid Interactions

Xyntha 250 Unit may interact with certain medications, including those that affect blood clotting. It is advisable to consult a healthcare professional before using this product alongside other treatments. Alcohol and certain supplements might also influence the effectiveness of Moroctocog Alfa.

Frequently Asked Questions

Xyntha 250 Unit is used to manage and prevent bleeding episodes in individuals with hemophilia A.

Xyntha 250 Unit is administered intravenously, typically by a healthcare professional.

Common side effects may include localized reactions at the injection site, headache, and nausea.

It is important to consult a healthcare professional before using Xyntha 250 Unit with other medications.

Precautions include monitoring for allergic reactions, informing healthcare providers about pre-existing conditions, and proper storage.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.